Discover how an innovative blood test can help optimize the clinical management of HPV-driven OPSCC

Join us at the AAO-HNSF 2021 Annual Meeting & OTO Experience
to learn about NavDx® – the first and only clinically validated circulating
tumor-tissue–modified HPV (TTMV®) DNA blood test that aids in the
optimal clinical management of HPV-driven cancer across the care continuum.1

To learn more about NavDx® stop by booth #1643
or visit our virtual booth at

We invite you to attend our
industry thought leader presentation,
Clinical Evidence of Novel Blood Test for
HPV-Driven Cancer Detection and Monitoring

Dr. Abie Mendelsohn, MD, FACS
Director, Head & Neck Robotic Surgery
University of California, Los Angeles, CA

Dr. Jiaxin Niu, MD, PhD
Associate Director, Head & Neck Cancer Program
Banner MD Anderson Cancer Center, AZ

Monday October 4, 10:00am – 11:00am PDT
in the Exhibit Hall Theater

We look forward to your visit!